Adipotide

Metabolic & weight Research compound (not approved for human use)

Adipose-vasculature-targeting proapoptotic peptidomimetic · also known as FTPP, Prohibitin-TP01, CKGGRAKDC-GG-D(KLAKLAK)2

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

Adipotide joins a targeting sequence that homes to a protein (prohibitin) on the blood vessels of white fat with a pro-apoptotic motif. In rodents and obese monkeys it caused loss of fat tissue and weight, but it also produced reversible kidney changes in the primate work. A single early human trial in men with prostate cancer and obesity was ended, and there is no meaningful human efficacy data.

Commonly reported dosing (5 mg vial)

Reconstituted with 1.5 mL → 3.333 mg/mL.

Also sold in 2 mg, 10 mg vials.

Phase	Dose	Volume	U-100 units
Starting	250 mcg	0.075 mL	7.5
Standard	500 mcg	0.15 mL	15
Higher	750 mcg	0.225 mL	22.5
Highest charted	1 mg	0.3 mL	30

Frequency: Once daily, subcutaneous · Half-life: Short; limited published pharmacokinetic data

Open in calculator

Commonly reported dose escalation

Weeks	Dose	Volume	U-100 units
Weeks 1-2	250 mcg	0.075 mL	7.5
Weeks 3-4	500 mcg	0.15 mL	15
Weeks 5-6	750 mcg	0.225 mL	22.5
Week 7+	1 mg	0.3 mL	30

Higher steps may need a larger vial or more than one draw. Escalation schedules vary; dosing decisions belong to a licensed clinician.

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
1.5 mL of bacteriostatic water is added slowly down the inside wall of the 5 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 3.33 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Lyophilized vials are commonly stored frozen (around -20 °C) and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C), protected from light, and not frozen.

How it works

The targeting domain binds prohibitin expressed on adipose vasculature, and the attached pro-apoptotic domain is thought to disrupt mitochondria in those vessel cells, reducing blood supply to fat tissue.

Researched for

Studied for white-fat reduction in obese mice.
Evaluated in obese rhesus monkeys, where weight loss and improved insulin handling were reported alongside reversible changes in kidney tubule function.

Notes

Dose figures here follow community-reported schedules (250 mcg stepped up to 1 mg daily); they are not derived from a completed human trial. Primate work used weight-based doses.
Kidney effects were the main toxicity signal in monkeys, which is why published chart schedules tend to escalate gradually.
A phase 1 study of the compound (registered as Prohibitin-TP01) in men with metastatic prostate cancer and obesity was terminated.
The same concentration (about 3.3 mg/mL) is reached by using 0.6, 1.5 or 3 mL for the 2, 5 or 10 mg vials.